Martti Hedman, Colorcon's CEO has commented: "Here at Colorcon, we recognise that huge efforts are ongoing around the world to contain and limit the spread of COVID-19 during this global pandemic and the great sacrifice being made in the healthcare services."
"We are proud to be a key part of the pharmaceutical supply chain and are endeavouring, as always, to provide unmatched quality and service to our customers worldwide — many of whom are developing and manufacturing essential and life-saving medicines."
"Colorcon’s importance has been categorised, by authorities and governments around the world, as “essential" or “life-sustaining,” which means we provide a critical link in the supply chain of medicines to hospitals, pharmacies and individual patients. As such, our customers rely on our global network and our Business Continuity Plan (BCP), which we activated to maintain the supply chain."
"Recent reports have highlighted drugs that are being evaluated for potential use to treat or lessen the effects of, COVID-19, and Colorcon’s products are used in some of these drugs. Therefore, it is very important and in the public interest that Colorcon continues to supply its coatings and excipients for these medicines."
"We are managing this supply while continuing to prioritise our commitment to the safety and health of our employees. We have activated our established Business Continuity Plan (BCP) and are managing inventory levels in accordance with that plan."
"Currently, all Colorcon manufacturing plants around the world are operational, including our seven film coating facilities. Our Technical, Regulatory and Business Teams continue to be available to help mitigate disruption to manufacturing and development projects."
"Therefore, although these are unprecedented times, Colorcon is well positioned to continue to provide the quality, service and support customers have come to expect from us."